nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—AGTR1—atherosclerosis	0.839	1	CbGaD
Azilsartan medoxomil—AGTR1—artery—atherosclerosis	0.00608	0.257	CbGeAlD
Azilsartan medoxomil—AGTR1—endothelium—atherosclerosis	0.00514	0.217	CbGeAlD
Azilsartan medoxomil—AGTR1—blood vessel—atherosclerosis	0.00474	0.2	CbGeAlD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Rosuvastatin—atherosclerosis	0.00446	0.0589	CcSEcCtD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Lovastatin—atherosclerosis	0.00378	0.0499	CcSEcCtD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Ezetimibe—atherosclerosis	0.00371	0.0489	CcSEcCtD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Simvastatin—atherosclerosis	0.00354	0.0467	CcSEcCtD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Pravastatin—atherosclerosis	0.0032	0.0422	CcSEcCtD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—ACE—atherosclerosis	0.00272	0.0495	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—KNG1—atherosclerosis	0.00247	0.0449	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—connective tissue—atherosclerosis	0.00243	0.103	CbGeAlD
Azilsartan medoxomil—Hyperuricaemia—Niacin—atherosclerosis	0.00241	0.0318	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Niacin—atherosclerosis	0.00228	0.03	CcSEcCtD
Azilsartan medoxomil—AGTR1—cardiovascular system—atherosclerosis	0.00211	0.0893	CbGeAlD
Azilsartan medoxomil—AGTR1—adipose tissue—atherosclerosis	0.00186	0.0787	CbGeAlD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—AGT—atherosclerosis	0.00172	0.0314	CbGpPWpGaD
Azilsartan medoxomil—Tasosartan—AGTR1—atherosclerosis	0.00148	0.218	CrCbGaD
Azilsartan medoxomil—AGTR1—liver—atherosclerosis	0.00131	0.0552	CbGeAlD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—NOS3—atherosclerosis	0.00127	0.023	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Ezetimibe—atherosclerosis	0.00126	0.0167	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00126	0.0166	CcSEcCtD
Azilsartan medoxomil—Olmesartan—AGTR1—atherosclerosis	0.00125	0.184	CrCbGaD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CX3CR1—atherosclerosis	0.00123	0.0224	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Rosuvastatin—atherosclerosis	0.00123	0.0162	CcSEcCtD
Azilsartan medoxomil—Telmisartan—AGTR1—atherosclerosis	0.0012	0.177	CrCbGaD
Azilsartan medoxomil—Angiopathy—Ezetimibe—atherosclerosis	0.00116	0.0153	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Niacin—atherosclerosis	0.00111	0.0146	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Lovastatin—atherosclerosis	0.00109	0.0144	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00107	0.0142	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Ezetimibe—atherosclerosis	0.00107	0.0142	CcSEcCtD
Azilsartan medoxomil—Angioedema—Lovastatin—atherosclerosis	0.00104	0.0137	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Simvastatin—atherosclerosis	0.00102	0.0135	CcSEcCtD
Azilsartan medoxomil—Angioedema—Ezetimibe—atherosclerosis	0.00102	0.0134	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Niacin—atherosclerosis	0.00102	0.0134	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PLG—atherosclerosis	0.00101	0.0183	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Simvastatin—atherosclerosis	0.000972	0.0128	CcSEcCtD
Azilsartan medoxomil—Candesartan—AGTR1—atherosclerosis	0.00097	0.143	CrCbGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—HRH1—atherosclerosis	0.000947	0.0172	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000943	0.0124	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Niacin—atherosclerosis	0.000939	0.0124	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Pravastatin—atherosclerosis	0.000925	0.0122	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Ezetimibe—atherosclerosis	0.000893	0.0118	CcSEcCtD
Azilsartan medoxomil—Angioedema—Niacin—atherosclerosis	0.000893	0.0118	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—EDNRA—atherosclerosis	0.000888	0.0162	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CCR2—atherosclerosis	0.000888	0.0162	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Ezetimibe—atherosclerosis	0.000884	0.0117	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL17A—atherosclerosis	0.000884	0.0161	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Pravastatin—atherosclerosis	0.000879	0.0116	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRH1—atherosclerosis	0.000847	0.0154	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—TGFB1—atherosclerosis	0.000837	0.0152	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000826	0.0109	CcSEcCtD
Azilsartan medoxomil—Fatigue—Lovastatin—atherosclerosis	0.0008	0.0106	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000786	0.0104	CcSEcCtD
Azilsartan medoxomil—Asthenia—Rosuvastatin—atherosclerosis	0.000786	0.0104	CcSEcCtD
Azilsartan medoxomil—Fatigue—Ezetimibe—atherosclerosis	0.000785	0.0104	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD40—atherosclerosis	0.000784	0.0143	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Rosuvastatin—atherosclerosis	0.000775	0.0102	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Niacin—atherosclerosis	0.000774	0.0102	CcSEcCtD
Azilsartan medoxomil—Telmisartan—PPARG—atherosclerosis	0.000758	0.112	CrCbGaD
Azilsartan medoxomil—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00075	0.00989	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Rosuvastatin—atherosclerosis	0.000749	0.00989	CcSEcCtD
Azilsartan medoxomil—Fatigue—Simvastatin—atherosclerosis	0.000749	0.00988	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—HRH1—atherosclerosis	0.000732	0.0133	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Rosuvastatin—atherosclerosis	0.000724	0.00956	CcSEcCtD
Azilsartan medoxomil—Rash—Rosuvastatin—atherosclerosis	0.000691	0.00911	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Rosuvastatin—atherosclerosis	0.00069	0.0091	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Niacin—atherosclerosis	0.000688	0.00908	CcSEcCtD
Azilsartan medoxomil—Fatigue—Pravastatin—atherosclerosis	0.000677	0.00893	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL4—atherosclerosis	0.000676	0.0123	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—F2—atherosclerosis	0.000672	0.0122	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Lovastatin—atherosclerosis	0.000666	0.00879	CcSEcCtD
Azilsartan medoxomil—Pruritus—Lovastatin—atherosclerosis	0.000657	0.00867	CcSEcCtD
Azilsartan medoxomil—Asthenia—Ezetimibe—atherosclerosis	0.000653	0.00862	CcSEcCtD
Azilsartan medoxomil—Nausea—Rosuvastatin—atherosclerosis	0.000651	0.00858	CcSEcCtD
Azilsartan medoxomil—Pruritus—Ezetimibe—atherosclerosis	0.000644	0.0085	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—INS—atherosclerosis	0.00064	0.0116	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Lovastatin—atherosclerosis	0.000635	0.00838	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—HRH1—atherosclerosis	0.000627	0.0114	CbGpPWpGaD
Azilsartan medoxomil—Losartan—AGTR1—atherosclerosis	0.000625	0.0921	CrCbGaD
Azilsartan medoxomil—Asthenia—Simvastatin—atherosclerosis	0.000623	0.00822	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Ezetimibe—atherosclerosis	0.000623	0.00822	CcSEcCtD
Azilsartan medoxomil—Pruritus—Simvastatin—atherosclerosis	0.000614	0.00811	CcSEcCtD
Azilsartan medoxomil—Dizziness—Lovastatin—atherosclerosis	0.000614	0.0081	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—UTS2—atherosclerosis	0.000611	0.0111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—UTS2—atherosclerosis	0.000603	0.011	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Ezetimibe—atherosclerosis	0.000602	0.00794	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL10—atherosclerosis	0.000601	0.0109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD40LG—atherosclerosis	0.000601	0.0109	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Simvastatin—atherosclerosis	0.000594	0.00784	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—CASR—atherosclerosis	0.000585	0.0107	CbGpPWpGaD
Azilsartan medoxomil—Rash—Lovastatin—atherosclerosis	0.000585	0.00772	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Lovastatin—atherosclerosis	0.000585	0.00772	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CX3CR1—atherosclerosis	0.000578	0.0105	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Simvastatin—atherosclerosis	0.000574	0.00758	CcSEcCtD
Azilsartan medoxomil—Rash—Ezetimibe—atherosclerosis	0.000574	0.00757	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Ezetimibe—atherosclerosis	0.000574	0.00757	CcSEcCtD
Azilsartan medoxomil—Asthenia—Niacin—atherosclerosis	0.000572	0.00755	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—atherosclerosis	0.00057	0.0104	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CX3CL1—atherosclerosis	0.000567	0.0103	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Niacin—atherosclerosis	0.000564	0.00744	CcSEcCtD
Azilsartan medoxomil—Asthenia—Pravastatin—atherosclerosis	0.000563	0.00743	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—FASLG—atherosclerosis	0.000559	0.0102	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Pravastatin—atherosclerosis	0.000555	0.00733	CcSEcCtD
Azilsartan medoxomil—Nausea—Lovastatin—atherosclerosis	0.000551	0.00728	CcSEcCtD
Azilsartan medoxomil—Rash—Simvastatin—atherosclerosis	0.000547	0.00722	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Simvastatin—atherosclerosis	0.000547	0.00722	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—UTS2—atherosclerosis	0.000546	0.00994	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Niacin—atherosclerosis	0.000546	0.0072	CcSEcCtD
Azilsartan medoxomil—Nausea—Ezetimibe—atherosclerosis	0.000541	0.00714	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Pravastatin—atherosclerosis	0.000537	0.00709	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—atherosclerosis	0.000534	0.00972	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Niacin—atherosclerosis	0.000527	0.00696	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CASR—atherosclerosis	0.000524	0.00953	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Pravastatin—atherosclerosis	0.000519	0.00685	CcSEcCtD
Azilsartan medoxomil—Nausea—Simvastatin—atherosclerosis	0.000516	0.0068	CcSEcCtD
Azilsartan medoxomil—Rash—Niacin—atherosclerosis	0.000503	0.00663	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Niacin—atherosclerosis	0.000502	0.00663	CcSEcCtD
Azilsartan medoxomil—Rash—Pravastatin—atherosclerosis	0.000495	0.00653	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Pravastatin—atherosclerosis	0.000495	0.00652	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—HRH1—atherosclerosis	0.000478	0.0087	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Niacin—atherosclerosis	0.000474	0.00625	CcSEcCtD
Azilsartan medoxomil—Nausea—Pravastatin—atherosclerosis	0.000466	0.00615	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL3—atherosclerosis	0.000462	0.00841	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL4—atherosclerosis	0.000454	0.00826	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CX3CR1—atherosclerosis	0.000452	0.00823	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NFKB1—atherosclerosis	0.000424	0.00771	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—EDNRA—atherosclerosis	0.000423	0.0077	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CNR2—atherosclerosis	0.000421	0.00765	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCR2—atherosclerosis	0.000418	0.0076	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—EDNRA—atherosclerosis	0.000418	0.0076	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK8—atherosclerosis	0.000417	0.00758	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GHRL—atherosclerosis	0.000412	0.0075	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—GHRL—atherosclerosis	0.000407	0.00741	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—UTS2—atherosclerosis	0.000404	0.00736	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CX3CR1—atherosclerosis	0.000388	0.00705	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CX3CL1—atherosclerosis	0.00038	0.00692	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—atherosclerosis	0.000379	0.00689	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—atherosclerosis	0.000369	0.00671	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK3—atherosclerosis	0.000364	0.00662	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—KNG1—atherosclerosis	0.000362	0.00659	CbGpPWpGaD
Azilsartan medoxomil—Losartan—ACE—atherosclerosis	0.000361	0.0532	CrCbGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.00036	0.00656	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—KNG1—atherosclerosis	0.000357	0.0065	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IFNG—atherosclerosis	0.000353	0.00643	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL4—atherosclerosis	0.000345	0.00629	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—atherosclerosis	0.00033	0.006	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—atherosclerosis	0.000328	0.00598	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—EDNRA—atherosclerosis	0.000327	0.00595	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—atherosclerosis	0.000327	0.00595	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—atherosclerosis	0.000324	0.00589	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL1B—atherosclerosis	0.000315	0.00573	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.00031	0.00564	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—UTS2—atherosclerosis	0.000308	0.0056	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—EDN1—atherosclerosis	0.000305	0.00555	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—EDN1—atherosclerosis	0.000301	0.00548	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL5—atherosclerosis	0.000299	0.00544	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CX3CR1—atherosclerosis	0.000295	0.00537	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CASR—atherosclerosis	0.000295	0.00537	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CX3CL1—atherosclerosis	0.00029	0.00527	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—atherosclerosis	0.000287	0.00522	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.00028	0.0051	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.00028	0.0051	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CNR2—atherosclerosis	0.000274	0.00499	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.000273	0.00497	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—atherosclerosis	0.000273	0.00497	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—HRH1—atherosclerosis	0.00027	0.00491	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—atherosclerosis	0.000267	0.00486	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—AGT—atherosclerosis	0.000253	0.00461	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—AGT—atherosclerosis	0.00025	0.00455	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—atherosclerosis	0.000245	0.00447	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HRH1—atherosclerosis	0.000245	0.00446	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—atherosclerosis	0.000245	0.00446	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.00024	0.00436	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL3—atherosclerosis	0.000236	0.00429	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—F2—atherosclerosis	0.000234	0.00426	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—F2—atherosclerosis	0.000231	0.0042	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—atherosclerosis	0.000229	0.00416	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	0.000226	0.00412	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDNRA—atherosclerosis	0.000213	0.00388	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR2—atherosclerosis	0.000213	0.00388	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	0.000209	0.00381	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GHRL—atherosclerosis	0.000208	0.00378	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL2—atherosclerosis	0.000206	0.00375	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000202	0.00368	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.0002	0.00365	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—KNG1—atherosclerosis	0.000183	0.00332	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL4—atherosclerosis	0.000177	0.00323	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—UTS2—atherosclerosis	0.000174	0.00317	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000168	0.00305	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CASR—atherosclerosis	0.000167	0.00304	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—atherosclerosis	0.000163	0.00296	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—UTS2—atherosclerosis	0.000158	0.00288	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CNR2—atherosclerosis	0.000155	0.00282	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000155	0.00282	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDN1—atherosclerosis	0.000154	0.0028	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL5—atherosclerosis	0.000153	0.00278	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CX3CR1—atherosclerosis	0.000151	0.00276	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CASR—atherosclerosis	0.000151	0.00276	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CX3CL1—atherosclerosis	0.000149	0.0027	CbGpPWpGaD
Azilsartan medoxomil—Losartan—ALB—atherosclerosis	0.000148	0.0218	CrCbGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HRH1—atherosclerosis	0.000145	0.00264	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CNR2—atherosclerosis	0.000141	0.00256	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000138	0.00251	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—AGT—atherosclerosis	0.000128	0.00232	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL3—atherosclerosis	0.000121	0.0022	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR2—atherosclerosis	0.000121	0.00219	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDNRA—atherosclerosis	0.000121	0.00219	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—F2—atherosclerosis	0.000118	0.00215	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GHRL—atherosclerosis	0.000118	0.00214	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOA4—atherosclerosis	0.000114	0.00207	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	0.000113	0.00206	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR2—atherosclerosis	0.00011	0.00199	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDNRA—atherosclerosis	0.00011	0.00199	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000109	0.00199	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GHRL—atherosclerosis	0.000107	0.00194	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL2—atherosclerosis	0.000105	0.00191	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL4—atherosclerosis	0.000105	0.00191	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—KNG1—atherosclerosis	0.000103	0.00188	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOA2—atherosclerosis	9.79e-05	0.00178	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KNG1—atherosclerosis	9.37e-05	0.0017	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—UTS2—atherosclerosis	9.33e-05	0.0017	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CX3CR1—atherosclerosis	8.95e-05	0.00163	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASR—atherosclerosis	8.95e-05	0.00163	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CX3CL1—atherosclerosis	8.78e-05	0.0016	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDN1—atherosclerosis	8.69e-05	0.00158	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCL5—atherosclerosis	8.63e-05	0.00157	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CNR2—atherosclerosis	8.32e-05	0.00151	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—atherosclerosis	8.32e-05	0.00151	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MMP3—atherosclerosis	8.3e-05	0.00151	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	8.28e-05	0.00151	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PRKCG—atherosclerosis	8.2e-05	0.00149	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDN1—atherosclerosis	7.9e-05	0.00144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL5—atherosclerosis	7.83e-05	0.00143	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PRKCG—atherosclerosis	7.45e-05	0.00136	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VWF—atherosclerosis	7.42e-05	0.00135	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOC3—atherosclerosis	7.37e-05	0.00134	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LDLR—atherosclerosis	7.32e-05	0.00133	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AGT—atherosclerosis	7.22e-05	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL3—atherosclerosis	7.15e-05	0.0013	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NCF1—atherosclerosis	6.85e-05	0.00125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—F2—atherosclerosis	6.67e-05	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AGT—atherosclerosis	6.55e-05	0.00119	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDNRA—atherosclerosis	6.47e-05	0.00118	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR2—atherosclerosis	6.47e-05	0.00118	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CYBA—atherosclerosis	6.44e-05	0.00117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CG—atherosclerosis	6.38e-05	0.00116	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PLAT—atherosclerosis	6.31e-05	0.00115	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GHRL—atherosclerosis	6.31e-05	0.00115	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PARP1—atherosclerosis	6.31e-05	0.00115	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—F2—atherosclerosis	6.06e-05	0.0011	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CG—atherosclerosis	5.8e-05	0.00105	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KNG1—atherosclerosis	5.53e-05	0.00101	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL2—atherosclerosis	5.4e-05	0.000982	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PLG—atherosclerosis	5.36e-05	0.000976	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SOCS3—atherosclerosis	5.08e-05	0.000924	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP3—atherosclerosis	4.9e-05	0.000892	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF2—atherosclerosis	4.88e-05	0.000888	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOB—atherosclerosis	4.74e-05	0.000862	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—atherosclerosis	4.7e-05	0.000855	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDN1—atherosclerosis	4.66e-05	0.000849	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL5—atherosclerosis	4.63e-05	0.000842	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LPL—atherosclerosis	4.53e-05	0.000824	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKCG—atherosclerosis	4.4e-05	0.000801	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SPP1—atherosclerosis	4.29e-05	0.00078	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—atherosclerosis	4.27e-05	0.000777	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDGFB—atherosclerosis	3.97e-05	0.000722	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AGT—atherosclerosis	3.87e-05	0.000704	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEP—atherosclerosis	3.79e-05	0.00069	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOE—atherosclerosis	3.79e-05	0.00069	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CAV1—atherosclerosis	3.76e-05	0.000684	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOA1—atherosclerosis	3.75e-05	0.000682	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ESR1—atherosclerosis	3.62e-05	0.000659	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—F2—atherosclerosis	3.58e-05	0.000651	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CG—atherosclerosis	3.42e-05	0.000623	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK3—atherosclerosis	3.28e-05	0.000597	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—INS—atherosclerosis	3.24e-05	0.00059	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL2—atherosclerosis	3.19e-05	0.00058	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1—atherosclerosis	3.13e-05	0.00057	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SERPINE1—atherosclerosis	2.98e-05	0.000542	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOS3—atherosclerosis	2.84e-05	0.000517	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—atherosclerosis	2.52e-05	0.000459	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT1—atherosclerosis	2.44e-05	0.000443	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—atherosclerosis	2.4e-05	0.000436	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—atherosclerosis	2.28e-05	0.000415	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFKB1—atherosclerosis	2.26e-05	0.000411	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK8—atherosclerosis	2.22e-05	0.000404	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT1—atherosclerosis	2.21e-05	0.000402	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—atherosclerosis	2.05e-05	0.000373	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—atherosclerosis	2.03e-05	0.000369	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK3—atherosclerosis	1.94e-05	0.000352	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—atherosclerosis	1.88e-05	0.000342	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—atherosclerosis	1.42e-05	0.000258	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT1—atherosclerosis	1.31e-05	0.000238	CbGpPWpGaD
